| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0081 | 0.8 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | -0.0094 | 0.8 |
| mRNA | CD-1530 | CTRPv2 | pan-cancer | AAC | 0.0092 | 0.8 |
| mRNA | AKT inhibitor VIII | GDSC1000 | pan-cancer | AAC | -0.0084 | 0.8 |
| mRNA | necrostatin-7 | CTRPv2 | pan-cancer | AAC | 0.0089 | 0.8 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.0084 | 0.8 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | 0.0085 | 0.8 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | GSK4112 | CTRPv2 | pan-cancer | AAC | -0.0086 | 0.8 |
| mRNA | AT-7519 | GDSC1000 | pan-cancer | AAC | 0.0068 | 0.8 |